A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

BACKGROUND: Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS). Pathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukamachi, Hiroshi, Kim, Seon-Kyu, Koh, Jiwon, Lee, Hye Seung, Sasaki, Yasushi, Yamashita, Kentaro, Nishikawaji, Taketo, Shimada, Shu, Akiyama, Yoshimitsu, Byeon, Sun-ju, Bae, Dong-Hyuck, Okuno, Keisuke, Nakagawa, Masatoshi, Tanioka, Toshiro, Inokuchi, Mikito, Kawachi, Hiroshi, Tsuchiya, Kiichiro, Kojima, Kazuyuki, Tokino, Takashi, Eishi, Yoshinobu, Kim, Yong Sung, Kim, Woo Ho, Yuasa, Yasuhito, Tanaka, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416873/
https://www.ncbi.nlm.nih.gov/pubmed/30866995
http://dx.doi.org/10.1186/s13046-019-1121-3

Ejemplares similares

Ejemplares similares